Anaplastic Large Cell Lymphoma, ALK-Positive

15 clinical trials · Condition

Record	Firm	Date
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (NCT03505554)	University of Milano Bicocca	2019-09-28
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms (NCT03493451)	BeiGene	2018-04-13
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma (NCT02729961)	University of Washington	2018-01-03
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625)	National Cancer Institute (NCI)	2017-09-27
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (NCT03113500)	City of Hope Medical Center	2017-05-25
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma (NCT02561273)	University of Nebraska	2015-09-28
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas (NCT02419287)	University of Milano Bicocca	2015-04-01
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (NCT01979536)	National Cancer Institute (NCI)	2013-11-13

Every clearance here is in the API, with alerts when new ones post.